NCT06284915已完成3 期
A Parallel-group, Prevention, Phase III, Modified Double-blind, 2-arm, Study to Investigate the Immunogenicity and Describe the Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared With Nimenrix® When Administered in a 1+1 Schedule in Healthy Infants and Toddlers at 6 and 12 Months of Age
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 840
- 试验地点
- 45
- 主要终点
- Geometric mean titers (GMTs) of Antibodies against meningococcal serogroups A, C, W and Y
研究概览
简要总结
This study is conducted to support a 2-dose series (1+1 vaccination schedule) for immunization of individuals from 6 months of age. The study is designed to evaluate the non-inferiority of the immunological response of MenACYW conjugate vaccine to Nimenrix® after the completion of the 2-dose series (1+1 vaccination schedule), with the first dose (priming dose) being given at 6-7 months of age to MenACWY- naïve healthy infants and the second dose (booster dose) given at 12-13 months of age. This study will also describe additional immunogenicity parameters and safety of MenACYW conjugate vaccine and Nimenrix® in the same population of participants.
详细描述
The study duration will be approximately 7 to 8.5 months (at least 7 months per participant).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
盲法说明
The study will be performed in a modified double-blind fashion:
- Investigators and study staff who conduct the safety assessment, and the participants parent/ legally acceptable representative will not know which study intervention is administered
- Only the study staff who prepare and administer the study intervention and are not involved with the safety evaluation will know which study intervention is administered
入排标准
- 年龄范围
- 6 Months 至 14 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Aged 6 to 7 months on the day of inclusion
- •Participants who are healthy as determined by medical evaluation including medical history, physical examination and judgment of the Investigator
排除标准
- •Participants are excluded from the study if any of the following criteria apply:
- •Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks) within the past 3 months
- •History of meningococcal infection, confirmed either clinically, serologically, or microbiologically
- •At high risk for meningococcal infection during the study (specifically but not limited to participants with persistent complement deficiency, with anatomic or functional asplenia, or participants traveling to countries with high endemic or epidemic disease)
- •Personal history of Guillain-Barré syndrome
- •Personal history of an Arthus-like reaction after vaccination with a tetanus toxoid-containing vaccine
- •Known systemic hypersensitivity to any of the study intervention components, or history of a life-threatening reaction to the study intervention(s) used in the study or to a product containing any of the same substances
- •Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]) on the day of study intervention administration. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided
- •Receipt of any vaccine (including COVID-19) and Meningococcal B vaccines) in the 4 weeks preceding the first and second study intervention administration or planned receipt of any vaccine (including COVID-19 and Meningococcal B vaccines) in the 4 weeks following any study intervention administration except for influenza vaccination, which may be received at least 2 weeks before or 2 weeks after the study interventions. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines.
- •Previous vaccination against meningococcal A, C, W, or Y disease with either the trial vaccine or another vaccine (i.e., mono- or quadrivalent meningococcal conjugate vaccine) containing serogroups A, C, Y, or W.
研究组 & 干预措施
Group 1: MenACYW conjugate vaccine
Experimental
Participants will receive MenACYW Conjugate Vaccine (MenQuadfi®): 2-dose schedule (1+1); dose 1 (priming dose) at 6-7 months of age and dose 2 (booster dose) at 12-13 months of age (MenQuadfi®)
干预措施: MenACYW conjugate vaccine (Biological)
Group 2: Nimenrix®
Active Comparator
Participants will receive Nimenrix®: 2-dose schedule (1+1); dose 1 (priming dose) at 6-7 months of age and dose 2 (booster dose) at 12-13 months of age
干预措施: MenACYW conjugate vaccine (Biological)
结局指标
主要结局
Geometric mean titers (GMTs) of Antibodies against meningococcal serogroups A, C, W and Y
时间窗: 30 days after dose 2 (booster dose) (+14 days)
Geometric mean titers after a 2-dose serie measured by serum bactericidal assays using human complement (hSBA)
Vaccine Seroresponse to meningococcal serogroups A, C, W and Y assessed by hSBA
时间窗: 30 days after dose 2 (booster dose) (+14 days)
Vaccine seroresponse after a 2-dose serie measured by hSBA
次要结局
- hSBA antibody titers ≥ 1:8 against meningococcal serogroups A, C, W and Y(30 days after dose 1 (priming dose) (+14 days))
- hSBA antibody titers against meningococcal serogroups A, C, W and Y(For infants 6-7 months old: Before and 30 days after dose 1 (priming dose) (+14 days) For toddlers12-13 months old: Before and 30 days after dose 2 (booster dose) (+14 days))
- hSBA antibody titers ≥ several pre-defined thresholds against meningococcal serogroups A, C, W and Y(For infants 6-7 months old: Before and 30 days after dose 1 (priming dose) (+14 days) For toddlers12-13 months old: Before and 30 days after dose 2 (booster dose) (+14 days)
- Percentage of Participants who achieved ≥4-fold rise in antibody titers over baseline measured by hSBA(For infants 6-7 months old: Before and 30 days after dose 1 (priming dose) (+14 days) For toddlers 12-13 months old: Before and 30 days after dose 2 (booster dose) (+14 days)
- hSBA meningococcal serogroups A, C, W and Y vaccine seroresponse(For infants 6-7 months old: Before and 30 days after dose 1 (priming dose) (+14 days) For toddlers12-13 months old: Before and 30 days after dose 2 (booster dose) (+14 days)
- Rabbit complement (rSBA) antibody titers against meningococcal serogroups A, C, W, and Y(For infants 6-7 months old: Before and 30 days after dose 1 (priming dose) (+14 days) For toddlers12-13 months old: Before and 30 days after dose 2 (booster dose) (+14 days)
- rSBA antibody titers ≥ several pre-defined thresholds against meningococcal serogroups A, C, W and Y(For infants 6-7 months old: Before and 30 days after dose 1 (priming dose) (+14 days) For toddlers 12-13 months old: Before and 30 days after dose 2 (booster dose) (+14 days)
- Percentage of Participants who achieved ≥4-fold rise in antibody titers over baseline measured by rSBA(For infants 6-7 months old: Before and 30 days after dose 1 (priming dose) (+14 days) For toddlers12-13 months old: Before and 30 days after dose 2 (booster dose) (+14 days)
- rSBA meningococcal serogroups A, C, W and Y vaccine seroresponse(For infants 6-7 months old: Before and 30 days after dose 1 (priming dose) (+14 days) For toddlers 12-13 months old: Before and 30 days after dose 2 (booster dose) (+14 days))
- Number of participants with immediate adverse events (AEs)(Within 30 minutes after each vaccination)
- Number of participants with solicited injection site reactions or systemic reactions(Within 7 days after each vaccination)
- Number of participants with unsolicited AEs(Up to 30 days after each vaccination)
- Number of participants with serious adverse events (SAEs)(From baseline to up to 7 months)
研究者
研究点 (45)
Loading locations...
相似试验
已完成
3 期
A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult ParticipantsEbolaNCT04228783Janssen Vaccines & Prevention B.V.974
已完成
2 期
Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's DiseaseAlzheimer's DiseaseNCT01117818Affiris AG335
已完成
3 期
Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in AdultsCovid19VaccinesNCT04651790Pontificia Universidad Catolica de Chile2,300
已完成
3 期
Year 3 Extension for Efficacy Follow-up in Subjects Vaccinated in Studies Rota-028, 029 or 030 (NCT00197210)Infections, RotavirusNCT00329745GlaxoSmithKline8,687
已完成
2 期
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive AdultsHIV InfectionsNCT00820846National Institute of Allergy and Infectious Diseases (NIAID)299